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With a little help from my enteric
microbial friends
Ben Berkhout *
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam
(CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Although the disciplines of bacteriology and virology frequently come together in the
setting of a diagnostic medical microbiology laboratory, the two scientific fields are usually
miles apart. The microbiologists basically form two non-overlapping groups of scientists,
the bacteriologists and virologists, which go to separate meetings and do not easily
intermingle. Some recent research findings about elegant virus–bacterium interactions
may change this situation. Obviously, interactions between these two microbes can
occur only when they colocalize, which most likely occurs in the gut/intestines where
1014 commensal bacteria reside (the microbiota). We review findings on the following
enteric microbial tandems: norovirus – Enterobacter cloacae, mouse mammary tumor
virus (MMTV) – bacterial lipopolysaccharide (LPS), poliovirus and reovirus – intestinal
bacteria. The close bacterium–virus interplay may also present options to develop unique
therapeutic strategies for those infected, and to prevent further virus spread, and thus
minimize the risk for the community.
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Norovirus Needs a Bacterium to Enter Cells
Members of the norovirus and sapovirus genera of theCaliciviridae family of small positive stranded
RNA viruses are infamous for causing outbreaks of gastroenteritis (stomach ache, nausea, and
diarrhea) in nursing homes and on cruise ships. Noroviruses have been estimated to be responsible
for 85% of these outbreaks, and there is no cure or vaccine available (1). Although the first norovirus
was identified nearly 50 years ago, it remained impossible to replicate human noroviruses in cell
culture and in small animal models in the laboratory. As a result, progress on the study of human
norovirus pathogenesis and the molecular replication mechanisms has lagged behind that of other
positive stranded RNA viruses, and development of antiviral drugs has also been hampered. The
absence of appropriate test systems also meant that the cellular tropism for this enteric virus
remainedunknown. The best surrogate system is themurine norovirus that does replicate in cultured
cells and mice. Several early findings suggested that murine norovirus strains require B cells (2–4).
In particular, mice lacking B cells exhibit reduced viral titers and the murine virus can be detected
in intestinal B cell zones in wild-type mice, but how these findings relate to human noroviruses
remained unclear.
Jones et al. recently reported that human norovirus needs help from Enterobacter cloacae, envi-
ronmental bacteria that may reside in the gut of hospitalized patients who received antibacterials, to
replicate in cultured human B cells (5). The key finding was that unfiltered stool samples can initiate
norovirus replication, whereas filtered samples demonstrate a firm infection block. This suggested
that a critical factor is removed during the standard practice of filtering human stool samples over
0.2 µm membranes to remove bacteria, hinting at help from the bacterial side. E. cloacae became
Frontiers in Medicine | www.frontiersin.org May 2015 | Volume 2 | Article 301
Berkhout Bacteria help human viral pathogens
the prime suspect because it was known to bindnorovirus (6). This
interaction involves glycan structures on the bacterial surface that
mimic blood type antigens on red blood cells, and synthetic gly-
cans can reproduce this effect. The virus–glycan interaction was
proposed to facilitate norovirus attachment to cells, as individuals
that lack these antigens are resistant to norovirus infection (7, 8).
To demonstrate bacterial involvement, filtered stool samples were
mixed with E. cloacae, which reestablished their ability to infect
human B cells (5). The effect is specific for E. cloacae as neither
Escherichia colinor the bacterial product lipopolysaccharide (LPS)
rescued norovirus infectivity.
Complementary results were obtained for the mouse norovirus
(5). This virus also infects B cells in vitro, and treatment of
norovirus-infected mice with antibiotics reduced the viral load. A
new twist to this story was added very recently in two studies, sug-
gesting that the gut microbiota may interfere with antiviral innate
immunity by quenching interferon-lambda (IFN-λ) signaling by
an as-yet undiscovered mechanism (9, 10).
It is clear that this new culture system for human norovirus
removes a major hurdle for many studies that were previously
impossible. To reduce the disease burden, better prevention and
control strategies for noroviruses are badly needed, and their
development is greatly facilitated by a simple culture system. The
recent findings also raise new research questions. First of all,
mechanistic details are still lacking on how glycans on the bac-
terial surface, but also free synthetic glycans, stimulate norovirus
attachment to B cells. Second, there may be significant variation
on the microbial side. Differences among the 25 highly variable
human norovirus genotypes can be expected because the glycan
binding site is hypervariable. As the human microbiome varies
from person to person, the magnitude and/or specificity of the
bacterial help will likely also vary between individuals.
Mouse Mammary Tumor Virus Uses
Bacterial LPS for Immune Evasion
A role for the intestinal microbiota in virus transmission was
reported for mouse mammary tumor virus (MMTV), which is
vertically transmitted from mothers to their offspring via mother
milk. MMTV is a member of the Retroviridae family that also
includes the human pathogens human immunodeficiency virus
(HIV) and human T-cell leukemia virus (HTLV), but there is no
human counterpart of MMTV. To establish a new infection, this
virus has to pass through mucosal surfaces that are rich in micro-
biota. It was recently reported that depletion of the commensal
microbiota in pregnant mice by broad-spectrum antibiotics has a
profound modulating effect on MMTV transmission to the first
offspring, even though the mothers continued high level MMTV
production in the milk (11). In a complementary approach, wild-
type mice transmitted MMTV much more efficiently to their
offspring than germ-free mice (11). Furthermore, reconstitution
of the germ-freemicewith a defined bacterial community restored
their ability to transmit MMTV, which may implicate a general
bacterial product, e.g., LPS as a general constituent of the outer
membrane of gram-negative bacteria, instead of a specific bacte-
rial strain. These combined results support a role of themicrobiota
in MMTV transmission through the oral route.
The putative role of LPS was studied in more detail. MMTV
ultracentrifugation led to comigration of LPS in the gradient.
LPS concentration by MMTV likely occurs in specific compart-
ments without affecting the global IL-10 levels, an immunosup-
pressive cytokine. Furthermore, this interaction potentiated the
ability of LPS to induce IL-10 production via engagement of the
toll-like receptor 4 (TLR4)-IL-6 cascade. TLR4-dependent IL-
10 production was already known to be required for MMTV
persistence (12), but it remained unclear whetherMMTVproteins
or products of the intestinal microbiota triggered TLRs. HIV-1
belongs, like MMTV, to the Retroviridae, and is also transmitted
to infants breastfed by HIV-positive mothers. Many biological
variables of this transmission route have been reported, e.g., bile-
salt stimulated lipase (BSSL) (13), but a role of the commensal
microbiota in retroviral pathogenesis should not be dismissed too
early. Many studies addressed the impact of the vaginal biome on
sexual transmission of HIV-1 (14, 15).
Poliovirus Needs LPS to Infect Cells
Poliovirus, the causative agent of poliomyelitis, is a human
enterovirus and member of the family of the Picornaviridae.
Poliovirus spreads via the fecal–oral route and will thus encounter
a multitude of microbes in the human gastrointestinal tract,
before it can establish infection. In fact, orally acquired poliovirus
performs a single replication cycle in the gastrointestinal tract
before dissemination throughout the body. In 95% of cases, only
a transient primary viremia occurs and the poliovirus infection
remains asymptomatic. In about 5% of cases, the virus spreads
and replicates in other sites such as reticuloendothelial tissue
and muscle, causing minor symptoms like fever, headache, and
sore throat. Paralytic poliomyelitis occurs in <1% of poliovirus
infections and occurs when the virus spreads into the central
nervous system.
Early studies indicated that the intestinalmicrobiome promotes
poliovirus replication and pathogenesis. For instance, antibiotic-
treated mice were less susceptible to poliovirus disease and
demonstrated minimal virus replication in the intestine (16).
However, themechanism remained unclear for some time. Robin-
son et al. recently demonstrated that bacterial LPS binds to
poliovirus particles, thereby increasing the virion stability and
infectivity (17). Simple incubation of poliovirus particles with
LPS (or peptidoglycan) delayed heat-induced release of the RNA
genome and thus maintained a higher infectivity of the virions
compared to mock-treated samples. Both molecules enhanced
the attachment of radiolabeled poliovirus to cells expressing the
poliovirus receptor or to the purified receptor protein.
The authors subsequently identified a specific amino acid
residue substitution in the viral capsid that affects virion sta-
bility and the sensitivity to LPS-mediated stabilization, possibly
by a direct effect on LPS binding (17). The Threonine-to-Lysine
substitution at position 99 is one of the attenuating mutations
in live-attenuated poliovirus vaccine strains and was reported to
affect LPS binding in some experimental settings. Themutant and
wild-type viruses behave identical with respect to cell attachment,
replication, and pathogenesis in mice, but the mutant virus was
unstable in feces, thus causing an environmental fitness cost.
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TABLE 1 | Pathogenic viruses that exploit intestinal bacteria.
Virus Enhancer Mechanism Impact
Norovirus Enteric bacteria
interfere with IFN-λ
Facilitate entry block
Innate immunity
Boost replication
MMTV Bacterial LPS Immune evasion Boost transmission
Poliovirus Bacterial LPS Virus stabilization Boost transmission
Reovirus Unknown Unknown Promote disease
Here, the virus uses the microbiota, more specifically a bacte-
rial product (LPS), to enhance its environmental stability, thus
promoting transmission to a new host.
Reovirus Also Needs Bacterial Help
The Reoviridae is a family of segmented, double-stranded RNA
viruses like rotavirus that can affect the gastrointestinal and res-
piratory tracts. “Reo” is derived from respiratory enteric orphan
viruses, which relates to the fact that a disease association was
not immediately apparent for some of these viruses. Most cases
in adults are mild or subclinical, but rotavirus can cause severe
diarrhea and intestinal distress in children.
A link with the microbiota first became apparent in the above
referenced poliovirus study in antibiotic-treated mice, which
were not only protected against poliovirus, but also against the
pathogenic effects of reovirus infection (16). Although reovirus
does not induce disease in wild-type mice, overt symptoms are
apparent in immunocompromised mice. Reovirus replication
causes obstruction of the biliary tract, resulting in hardened feces,
but also pathology like enlarged Peyer’s patches. These effects
were not observed in antibiotic-treated mice, with a concomitant
reduction of the reovirus titers compared to untreated animals.
Mechanistic details of the microbiota-induced protection remain
currently unknown.
Common Themes and Remaining
Questions
Microbiota are advantageous for the host for several reasons, e.g.,
for homeostatic functions of the mucosa and for limiting bacterial
pathogen colonization. However, recent reports suggest that viral
pathogens may utilize the microbiota to boost their replication
and/or transmission. Four examples of pathogenic viruses that
exploit the surrounding microbial community were discussed. It
is likely that commensal bacteria may contribute to the trans-
mission of an array of viruses, not only enteric pathogens, and
that this list will grow in the near future. The main players and
their functional interplay are summarized in Table 1. Norovirus
interacts with glycans on the surface of the intestinal E. cloa-
cae to facilitate attachment to the target B cells. MMTV virion
particles are stabilized by interaction with LPS, thus boosting
the transmission rate. Poliovirus studies indicate that bacterial-
primed virus shows enhanced receptor binding. The reovirus
studies are not yet very conclusive, but the antibiotic effect on
disease induction is apparent. For all cases, some importantmech-
anistic details are still lacking that will be addressed in future
research.
Although a limited number of virus–bacterial tandems have
been studied thus far, it appears that orally transmitted viruses
do efficiently exploit the gut microbiota in one way or the other
for transmission. Microbiota is predominantly located in the gut
and we reviewed virus–bacterial interactions that occur at this
location, but bacteria are also found at numerous other sites
on the human body, including the skin, respiratory tract, and
urogenital tract. Different viruses do navigate one ormore of these
sites, arguing that functional virus–microbiota interactions may
bemuchmore common than previously anticipated. Next genera-
tion sequencing techniques are likely to revolutionize the study of
this type of cross-kingdom virome–microbiota interactions, e.g.,
the interplay of the human papillomavirus with cervicovaginal
microbiota (18). Although we focused on virus–bacterial syn-
ergy, intestinal microbiota can also antagonize viruses and play
a protective role, as for instance been reported for rotavirus and
influenza virus (19–21). Other pathogens may also exploit the
intestinalmicrobiota for their propagation. For instance, intestinal
microbes induce egg hatching of an intestinal nematode in mice
(22). Enteric viruses interact with commensal bacteria via recog-
nition of surface glycans and this boosts – directly or indirectly –
viral replication.
Microbiota effects may also be indirect via their interaction
with the innate and adaptive immune systems (23). Certain com-
ponents of the microbiota have been shown to trigger inflam-
matory responses, whereas others induce anti-inflammatory
responses. To add to the complexity, viral infections may also
affect the microbiome composition. For instance, human studies
of airway microbiota demonstrated that the composition of the
respiratory microbiota can be modified by viral infection (24).
Understanding how themicrobiota interacts with viruses at the
molecular mechanistic level may inform future vaccine strategies
and the development of novel antiviral drugs. In fact, given this
close viral–bacterial collaborations, antibiotic treatment may –
on top of the antibacterial effect – impose an indirect antiviral
effect. The therapeutic use of bacteriophages may, through their
impact on components of the microbiota, indirectly affect their
viral counterparts that infect mammalian cells.
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